Europe and Japan Allergy Immunotherapy Market, by Treatment (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), by Allergy Type (Allergy Rhinitis, Allergy Asthma, Pollen Allergies {Cedar, Birch, Oak and Others}, Pet Allergy {Cats, Dog

Europe and Japan Allergy Immunotherapy Market, by Treatment (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), by Allergy Type (Allergy Rhinitis, Allergy Asthma, Pollen Allergies {Cedar, Birch, Oak and Others}, Pet Allergy {Cats, Dogs and Other Pets}, Birds Allergy and Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (Europe and Japan) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Immunotherapy is a preventive treatment for allergic reactions which are caused by substances such as grass pollens, house dust mites and bee venom. While providing immunotherapy treatment to patients, the dose of the drug is gradually increased to which the person is allergic. Immunotherapy also reduces the inflammation that characterizes rhinitis and asthma. Allergy shots, also known as subcutaneous immunotherapy (SCIT), is the most commonly used immunotherapy and this is the only treatment available that actually changes the immune system, making it possible to prevent development of new allergies and asthma.

Market Dynamics

Market players are involved in research and development activities for development of drugs for allergy immunotherapy and this is expected to drive growth of the Europe and Japan allergy immunotherapy market, over the forecast period. For instance, in May 2018, Stallergenes Greer, a biopharmaceutical company, announced positive results for its phase III clinical trial which was carried out, in order to evaluate the efficacy and safety of its sublingual allergy immunotherapy tablet STAGR320, for the treatment of house dust mite.

Key players are engaged in receiving approvals for their drugs, from the regulatory authorities and this is expected to drive growth of the Europe and Japan allergy immunotherapy market, over the forecast period. For instance, in November 2018, Stallergenes Greer, a biopharmaceutical company, received approval from the U.S. Food and Drug Administration (US FDA), for the extension of the indication for Oralair, for the treatment of patients with grass pollen-induced allergic rhinitis.

Moreover, in September 2018, Torii Pharmaceutical Co., Ltd. announced that Japan’s Ministry of Health, Labour and Welfare had approved the New Drug Application (NDA) for the Japanese cedar sublingual allergy immunotherapy (SLIT) tablet, i.e, CEDARCURE.

Key features of the study:

• This report provides an in-depth analysis of the Europe and Japan allergy immunotherapy market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the Europe and Japan allergy immunotherapy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Novartis International AG, Merck & Co., Inc., Aimmune Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., HAL Allergy B.V., Stallergenes Greer, ALK-Abelló A/S, Allergy Therapeutics Plc, Torii Pharmaceutical Co., Ltd., DESENTUM OY
• Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The Europe and Japan allergy immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe and Japan allergy immunotherapy market

Detailed Segmentation:

• Europe and Japan Allergy Immunotherapy Market, By Treatment:
• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
• Europe and Japan Allergy Immunotherapy Market, By Allergy Type:
• Allergy Rhinitis
• Allergy Asthma
• Pollen Allergies
• Cedar
• Birch
• Oak
• Others
• Pet Allergy
• Cats
• Dogs
• Other Pets
• Birds Allergy
• Others
• Europe and Japan Allergy Immunotherapy Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Europe and Japan Allergy Immunotherapy Market, By Region:
• Europe
• By Country:
• U.K.
• Germany
• Italy
• France
• Spain
• Denmark
• Sweden
• Poland
• Belgium
• Netherlands
• Russia
• Rest of Europe
• Japan
• Company Profiles
• Novartis International AG *
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
• Merck & Co., Inc.
• Aimmune Therapeutics, Inc.
• Regeneron Pharmaceuticals, Inc.
• HAL Allergy B.V.
• Stallergenes Greer
• ALK-Abelló A/S
• Allergy Therapeutics Plc
• Torii Pharmaceutical Co., Ltd.
• DESENTUM OY

“*” marked represents similar segmentation in other categories in the respective section.